Compare $INTI vs $NEUP | Chartloom

Compare

$INTI vs $NEUP

Inhibitor Therapeutics Inc · Neuphoria Therapeutics Inc

INTI

Inhibitor Therapeutics Inc

NEUP

Neuphoria Therapeutics Inc

Compare $INTI vs $NEUP

Comparing Inhibitor Therapeutics Inc and Neuphoria Therapeutics Inc

INTIInhibitor Therapeutics Inc

NEUPNeuphoria Therapeutics Inc

INTIInhibitor Therapeutics Inc

Market cap

$17M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

108.5%

52W performance

127.9%

FCF yield

-19.1%

NEUPNeuphoria Therapeutics Inc

Market cap

$18M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-92.5%

YTD performance

-12.0%

52W performance

-81.7%

FCF yield

-68.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

INTI

NEUP

Detailed metrics comparison

INTI

Inhibitor Therapeutics Inc

NEUP

Neuphoria Therapeutics Inc

Market Cap

INTI$17M

NEUP$18M

Enterprise Value

INTI$16M

NEUP$-2M

Price

INTI$0.10

NEUP$3.36

P/E Ratio

INTIN/A

NEUPN/A

P/S Ratio

INTI4.25x

NEUP15.45x

EV/Sales

INTI4.12x

NEUP-1.44x

EV/EBITDA

INTI1.61x

NEUP0.00x

P/B Ratio

INTI4,922.43x

NEUP0.76x

P/FCF Ratio

INTIN/A

NEUPN/A

EV/FCF

INTI-5.09x

NEUP0.14x

PEG Ratio

INTIN/A

NEUPN/A

Forward P/E (NTM)

INTIN/A

NEUPN/A

Forward P/S (NTM)

INTIN/A

NEUPN/A

Revenue (TTM)

INTI$0

NEUP$1M

Revenue Growth (YoY)

INTIN/A

NEUP-92.5%

Forward Rev Growth

INTI0.0%

NEUP0.0%

Gross Margin (TTM)

INTI20.9%

NEUP0.0%

Operating Margin (TTM)

INTI0.0%

NEUP0.0%

EBITDA Margin (TTM)

INTI0.0%

NEUP-779.0%

Net Margin (TTM)

INTI0.0%

NEUP-1145.6%

FCF Margin (TTM)

INTIN/A

NEUP-1052.0%

Net Income (TTM)

INTI$-3M

NEUP$-13M

FCF (TTM)

INTI$-3M

NEUP$-12M

EPS (TTM)

INTI$0.00

NEUP-$2.49

ROE (TTM)

INTI-33792.0%

NEUP-5591.0%

ROA (TTM)

INTI-12210.0%

NEUP-4222.0%

ROIC (TTM)

INTI-33792.0%

NEUP-5583.0%

Cash

INTI$516K

NEUP$20M

Debt

INTI$0

NEUP$34K

Net Cash/Debt

INTI$516K

NEUP$20M

Current Ratio (TTM)

INTI3.36x

NEUP27.85x

Quick Ratio (TTM)

INTI2.95x

NEUP27.33x

Debt/Equity (TTM)

INTI0.00x

NEUP0.00x

Debt/Assets (TTM)

INTI0.0%

NEUP0.0%

Interest Coverage (TTM)

INTIN/A

NEUPN/A

Net Debt/EBITDA (TTM)

INTI0.00x

NEUP0.00x

Beta

INTI-0.79

NEUP0.76

52W Performance

INTI127.9%

NEUP-81.7%

YTD Performance

INTI108.5%

NEUP-12.0%

% from 52W High

INTI-21.0%

NEUP-82.5%

% from 52W Low

INTI180.0%

NEUP5.3%

Asset Turnover (TTM)

INTI0.50x

NEUP0.04x

FCF Yield (TTM)

INTI-19.1%

NEUP-68.1%

Earnings Yield (TTM)

INTI-15.9%

NEUP-74.1%

Dividend Yield (TTM)

INTIN/A

NEUPN/A

Rule of 40

INTI0.0

NEUP-1,144.5

EV/GP/RG

INTIN/A

NEUPN/A

Ticker research

View INTI research View NEUP research

Metric	INTI Inhibitor Therapeutics Inc	NEUP Neuphoria Therapeutics Inc
Market & Valuation
Market Cap	$17M	$18M
Enterprise Value	$16M	$-2M
Price	$0.10	$3.36
P/E Ratio	N/A	N/A
P/S Ratio	4.25x	15.45x
EV/Sales	4.12x	-1.44x
EV/EBITDA	1.61x	0.00x
P/B Ratio	4,922.43x	0.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.09x	0.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$1M
Revenue Growth (YoY)	N/A	-92.5%
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	20.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-779.0%
Net Margin (TTM)	0.0%	-1145.6%
FCF Margin (TTM)	N/A	-1052.0%
Net Income (TTM)	$-3M	$-13M
FCF (TTM)	$-3M	$-12M
EPS (TTM)	$0.00	-$2.49
ROE (TTM)	-33792.0%	-5591.0%
ROA (TTM)	-12210.0%	-4222.0%
ROIC (TTM)	-33792.0%	-5583.0%
Financial Health
Cash	$516K	$20M
Debt	$0	$34K
Net Cash/Debt	$516K	$20M
Current Ratio (TTM)	3.36x	27.85x
Quick Ratio (TTM)	2.95x	27.33x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.79	0.76
52W Performance	127.9%	-81.7%
YTD Performance	108.5%	-12.0%
% from 52W High	-21.0%	-82.5%
% from 52W Low	180.0%	5.3%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.04x
FCF Yield (TTM)	-19.1%	-68.1%
Earnings Yield (TTM)	-15.9%	-74.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,144.5
EV/GP/RG	N/A	N/A
Ticker research	View INTI research	View NEUP research

Valuation

P/S Ratio

INTI

4.25x

NEUP

15.45x

EV/FCF

INTI

-5.09x

NEUP

0.14x

Growth & revenue

Revenue Growth TTM

NEUP

-92.5%

Forward Revenue Growth

INTI

0.0%

NEUP

0.0%

Profitability & performance

Gross Margin

INTI

20.9%

NEUP

0.0%

ROE

NEUP

-5591.0%

INTI

-33792.0%

FCF Yield %

INTI

-19.1%

NEUP

-68.1%

52-Week Performance

INTI

127.9%

NEUP

-81.7%

Detailed metrics comparison

INTI

Inhibitor Therapeutics Inc

NEUP

Neuphoria Therapeutics Inc

Market Cap

INTI$17M

NEUP$18M

Enterprise Value

INTI$16M

NEUP$-2M

Price

INTI$0.10

NEUP$3.36

P/E Ratio

INTIN/A

NEUPN/A

P/S Ratio

INTI4.25x

NEUP15.45x

EV/Sales

INTI4.12x

NEUP-1.44x

EV/EBITDA

INTI1.61x

NEUP0.00x

P/B Ratio

INTI4,922.43x

NEUP0.76x

P/FCF Ratio

INTIN/A

NEUPN/A

EV/FCF

INTI-5.09x

NEUP0.14x

PEG Ratio

INTIN/A

NEUPN/A

Forward P/E (NTM)

INTIN/A

NEUPN/A

Forward P/S (NTM)

INTIN/A

NEUPN/A

Revenue (TTM)

INTI$0

NEUP$1M

Revenue Growth (YoY)

INTIN/A

NEUP-92.5%

Forward Rev Growth

INTI0.0%

NEUP0.0%

Gross Margin (TTM)

INTI20.9%

NEUP0.0%

Operating Margin (TTM)

INTI0.0%

NEUP0.0%

EBITDA Margin (TTM)

INTI0.0%

NEUP-779.0%

Net Margin (TTM)

INTI0.0%

NEUP-1145.6%

FCF Margin (TTM)

INTIN/A

NEUP-1052.0%

Net Income (TTM)

INTI$-3M

NEUP$-13M

FCF (TTM)

INTI$-3M

NEUP$-12M

EPS (TTM)

INTI$0.00

NEUP-$2.49

ROE (TTM)

INTI-33792.0%

NEUP-5591.0%

ROA (TTM)

INTI-12210.0%

NEUP-4222.0%

ROIC (TTM)

INTI-33792.0%

NEUP-5583.0%

Cash

INTI$516K

NEUP$20M

Debt

INTI$0

NEUP$34K

Net Cash/Debt

INTI$516K

NEUP$20M

Current Ratio (TTM)

INTI3.36x

NEUP27.85x

Quick Ratio (TTM)

INTI2.95x

NEUP27.33x

Debt/Equity (TTM)

INTI0.00x

NEUP0.00x

Debt/Assets (TTM)

INTI0.0%

NEUP0.0%

Interest Coverage (TTM)

INTIN/A

NEUPN/A

Net Debt/EBITDA (TTM)

INTI0.00x

NEUP0.00x

Beta

INTI-0.79

NEUP0.76

52W Performance

INTI127.9%

NEUP-81.7%

YTD Performance

INTI108.5%

NEUP-12.0%

% from 52W High

INTI-21.0%

NEUP-82.5%

% from 52W Low

INTI180.0%

NEUP5.3%

Asset Turnover (TTM)

INTI0.50x

NEUP0.04x

FCF Yield (TTM)

INTI-19.1%

NEUP-68.1%

Earnings Yield (TTM)

INTI-15.9%

NEUP-74.1%

Dividend Yield (TTM)

INTIN/A

NEUPN/A

Rule of 40

INTI0.0

NEUP-1,144.5

EV/GP/RG

INTIN/A

NEUPN/A

Ticker research

View INTI research View NEUP research

Metric	INTI Inhibitor Therapeutics Inc	NEUP Neuphoria Therapeutics Inc
Market & Valuation
Market Cap	$17M	$18M
Enterprise Value	$16M	$-2M
Price	$0.10	$3.36
P/E Ratio	N/A	N/A
P/S Ratio	4.25x	15.45x
EV/Sales	4.12x	-1.44x
EV/EBITDA	1.61x	0.00x
P/B Ratio	4,922.43x	0.76x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.09x	0.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$1M
Revenue Growth (YoY)	N/A	-92.5%
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	20.9%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-779.0%
Net Margin (TTM)	0.0%	-1145.6%
FCF Margin (TTM)	N/A	-1052.0%
Net Income (TTM)	$-3M	$-13M
FCF (TTM)	$-3M	$-12M
EPS (TTM)	$0.00	-$2.49
ROE (TTM)	-33792.0%	-5591.0%
ROA (TTM)	-12210.0%	-4222.0%
ROIC (TTM)	-33792.0%	-5583.0%
Financial Health
Cash	$516K	$20M
Debt	$0	$34K
Net Cash/Debt	$516K	$20M
Current Ratio (TTM)	3.36x	27.85x
Quick Ratio (TTM)	2.95x	27.33x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.79	0.76
52W Performance	127.9%	-81.7%
YTD Performance	108.5%	-12.0%
% from 52W High	-21.0%	-82.5%
% from 52W Low	180.0%	5.3%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.04x
FCF Yield (TTM)	-19.1%	-68.1%
Earnings Yield (TTM)	-15.9%	-74.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,144.5
EV/GP/RG	N/A	N/A
Ticker research	View INTI research	View NEUP research